1 and no
1 and no. GSLCs (DCs) by fetal bovine serum. After exposure to BPA for 24 h at (+)-Talarozole 25 ppm in 5% CO2 incubator, we immune-stained them with twenty stem cell markers, anti-Ki-67, anti-BPA and anti-CD98 (heterodimer that forms the large BPA transporter) antibodies and analyzed them with Cytof. The percentage of BPA+ or CD98+ cells with stem cell markers (Oct3/4, Nestin, SOX2, Musashi-1, PDGFR, Notch2, Nanog, STAT3 and C-myc, among others) was 2C4 times larger among GSLCs than among DCs. Analyses of in vivo orthotopic tumor also indicated that 100% of SOX2+ or Nestin+ GSLCs were BPA+, whereas only 36.9% of glial fibrillary acidic protein (GFAP)+ DCs were BPA+. Therefore, GSLCs may take up BPA and could be targeted by BNCT. mutation-negative GBM [7]. Another potential reason may be the heterogeneous distribution of BPA in the (+)-Talarozole tumor, which consists of heterogeneous clones. Previous preclinical studies have reported heterogeneous distribution of BPA inside the peripheral (thigh) tumor using a melanoma or squamous cell carcinoma mouse model and indicated a relationship between the uptake of BPA and cell proliferation [8,9]. However, using quantitative subcellular imaging with secondary ion mass spectrometry, other studies of BPA showed that T98 GBM mitotic cells contain a significantly lower amount of boron in comparison with interphase cells [10]. Furthermore, Detta and Cruickshank reported that the uptake of BPA was antagonized by pretreatment with phenylalanine or a specific inhibitor of LAT-1, and the number of LAT-1-expressing cells was three times higher than Rabbit Polyclonal to BRI3B that of cells expressing proliferating cell number antigen (PCNA) in glioma patient tumor samples (71.5 17.02% versus 23.8 16.5%; 0.0001; = 38 GBM and metastatic tumors) [11]. These results indicate that non-proliferating cells could also take up BPA through LAT1. Recent studies have shown that glioma stem cells (GSCs), a small subpopulation of tumor cells, are responsible for (+)-Talarozole tumor resistance to radiation and chemotherapy, and the stemness, quiescence and therapy resistance are maintained by GSC niches in the tumor microenvironment [12,13]. However, BPA uptake in GSCs is largely unknown. Therefore, in this study, we investigated whether BPA is taken up by GSCs using mass cytometry (in vitro) and a mouse orthotopic tumor model (in vivo). We established two patient-derived glioma stem-like cells (GSLCs, named no. one and no. two) and (+)-Talarozole their differentiated cells. Here, we report the possibility of BPA uptake by GSLCs. 2. Results 2.1. Differentiation Was Induced to Patient-Derived GSLCs by Fetal Bovine Serum We established two GSLC lines, no. one and two, and induced differentiation by exposure to medium containing 10% fetal bovine serum (FBS) for 24 h. We examined two (+)-Talarozole differentiation markers, glial fibrillary acidic protein (GFAP) for astrocytes and neuron-specific beta-III tubulin (Tuj1) for neurons. The differentiation markers GFAP and Tuj1 were expressed at higher levels in differentiated cells compared with GSLCs (Figure 1a, b). In contrast, the expressions of GSC markers (Oct3/4, SOX2, Nestin, PDGFR, Nanog and STAT3) were decreased in differentiated cells after exposure to 10% FBS medium. Musashi-1, CD133, CD49f, Notch2, CD44, CXCR4 and c-Myc were decreased only in no. two cells after exposure to 10% FBS medium. CD171 expression increased in no. one cells and CD144 showed no change in both cell lines after.